Cypher® versus Taxus®: The stent war

Expert Opinion on Investigational Drugs

Volumn 15, Issue 12, 2006, Pages 1537-1544

  Shafiq, Nusrat ^a   Malhotra, Samir ^a   Pandhi, Promila ^a   Behl, Ajay ^a   Sharma, Yash Paul ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Complex lesions; Coronary artery disease; Cypher ; Percutaneous coronary intervention; Stents; Texus

Indexed keywords

PACLITAXEL; PLACEBO; POLYMER; RAPAMYCIN; TRANILAST;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG IMPLANT; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; STENT; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; DRUG IMPLANTS; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33845228702     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.12.1537     Document Type: Review

References (48)

1. KASTRATI DG, KARVOUNI E, IOANNIDIS JP: Meta-analysis comparing drug-eluting stents with bare metal stents. Am. J. Cardiol. (2005) 95:640-643.
2. SHAFIQ N, MALHOTRA S, PANDHI P et al: A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease. Br. J. Clin. Pharmacol. (2005) 59:94-101.
3. ROIRON C, SANCHEZ P, BOUZAMONDO A, LECHAT P, MONTALESCOT G: Drug eluting stents: an updated meta-analysis of randomized controlled trials. Meta-analysis comparing drug-eluting stents with bare metal stents. Heart (2006) 92:641-649.
4. BABAPULLE MN, JOSEPH L, BELISLE P et al.: A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet (2004) 364:583-591.
5. HILL RA, DUNDAR Y, BAKHAI A et al.: Drug-eluting stents: an early systematic review to inform policy. Eur. Heart J. (2004) 25:902-919.
6. LORDSJ, HOWARD K, ALLEN F et al: A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med. J. Aust. (2005) 183:464-471.
7. COY JJ, STAUFFER JC, SIEGENTHALER M et al: A prospective randomized comparison between paclitaxel and sirolimus in the real world of interventional cardiology. J. Am. Coll. Cardiol. (2005) 45:308-311.
8. ONG AT, SERRUYS PW, AOKI J et al.: The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J. Am. Coll. Cardiol. (2005) 45:1135-1141.
9. KASTARATI A, MEHILLI J, BECKERATH NV. Sirolimus-eluting stent or paclitaxel-eluting stent versus balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA (2005) 293:165-171.
10. JOSÉ SUÁREZ DE LEZO J, MEDINA A et al: Drug-eluting stent for complex lesions: latest angiographic data from the randomized rapamycin versus paclitaxel CORPAL study. J. Am. Coll. Cardiol. (2005) 45:75A (Abstract 1150-1144).
11. DIBRA A, KASTARATI A, MEHILLI J et al: ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N. Engl. J. Med. (2005) 353:663-670.
12. MORICE MC, COLOMBO A, MEIER B et al; REALITY TRIAL INVESTIGATORS: Sirolimus- versus paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA (2006) 295:937-938.
13. BENNETT MR: In scent stenosis: pathology and implications for development of drug eluting stents. Heart (2003) 89:218-230.
14. KRENSKY AM, VINCENTI F, BENNETT WM: Immunosuppressants, tolerogens and immunostimulants. In: Goodmand & Gilman's the pharmacological basis of therapeutics. Brunton LL, Lazo JS, Parker KL (Eds), McGraw Hill Publishers, New York, USA (2006):1405-1432.
15. CHABNER BA, AMREIN PC, DRUKER B et al.: Antineoplastic agents. In: Goodmand & Gilman's the pharmacological basis of therapeutics. Brunton, Lazo JS, Parker KL (Eds), McGraw Hill Publishers, New York, USA (2006):1315-1404.
16. KASTRATI A, DIBRA A, EBERLE S et al: Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA (2005) 294:819-825.
17. BIONDI-ZOCCAI GG, LOTRIONTE M, ABBATE A et al: Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. Int. J. Cardiol. (2005) (In Press).
18. SIDHU S, SHAFIQ N, MALHOTRA S et al: A meta-anatysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease. Br. J. Clin. Pharmacol. (2006) 61:720-726.
19. RADKE PW, KAISER A, FROST C et al: Outcome after treatment of coronary in-stent restenosis: results from a systematic review using meta-analysis techniques. Eur. Heart. J. (2003) 24:266-273.
20. ELEZI S, KASTRATI A, HADAMITZKY M et al.: Clinical and angiographic follow-up after balloon angioplasty with provision stenting for coronary in-stent restenosis. Catheter. Cardiovasc. Interv. (1999) 4:151-156.
21. ALBIERO R, SILBER S, DI MARIO C et al.: Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the Restenosis Cutting Balloon Evaluation Trial (RESCUT). J. Am. Coll. Cardiol. (2004) 43:943-949.
22. HOLMES DR, LEON MB, MOSES JW et al.: Analysis of 1-year clinical outcomes in the SIRIUS Trial. A randomized trial of a sirolimus-eluting stent versus a standard scent in patients at high risk for coronary restenosis. Circulation (2004) 109:634-640.
23. STONE GW, ELLIS SC, COX E et al.: One year clinical results with the slow-release polymer-based, paclitaxel-eluting TAXUS stent. The TAXUS IV Trial. Circulation (2004) 109:1942-1947.
24. SINGH M, GERSH BJ, McCLELLAND RL et al: Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2004) 109:2727-2731.
25. FINN AV, PALACIOS IF, KASTARATI A et al: Drug eluting stents for diabetes mellitus. A rush to judgement? J. Am. Coll. Cardiol, (2005) 45:479-483.
26. STONE GW, ELLIS SG, CANNON L et al.: TAXUS V Investigators comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA (2005) 294:1215-1223.
27. MARZOCCHI A, PIOVACCARI G, MANARI A et al.: Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events. Am. J. Cardiol. (2005) 95:1409-1414.
28. COSGRAVEJ, AGOSTONI P, GEL et al: Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting scents in complex coronary lesions. Am. J. Cardiol (2005) 96:1663-1668.
29. KAMINENI R, HEUSER RR: New approaches to long lesions. J. Interv. Cardiol. (2004) 17:405.
30. KIM YH, PARK SW, LEE CW et al.: Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter. Cardiovasc. Interv. (2006) 67(2):181-187.
31. CHIEFFO A, COLOMBO A: Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial? Nat. Clin. Pract. Cardiovasc. Med. (2005) 2:396-400.
32. VALGIMIGLI M, VAN MIEGHEM CA, ONG AT et al.: Short and long term clinical outcome after drug eluting stent implantation for the percutaneous treatment of left main coronary artery disease, insights from the Rapamycin-Eluting and Taxus Scent Evaluated at Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation (2005) 111:1383-1389.
33. PARK SJ, KIM YH, LEE BK et al.: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. Comparison with bare metal stent implantation. J. Am. Coll Cardiol. (2005) 45:351-356.
34. CHIEFFO R, STANKOVIC G, BONIZZONI E et al.: Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation (2005) 111:791-795.
35. LEE MS, KAPOOR N, JAMAL F et al: Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug eluting stents for unprotected left main coronary artery disease. J. Am. Coll. Cardiol. (2006) 47:864-870.
36. PRICE MJ, CRISTEA E, SAWHNEY N et al.: Serial angiographic follow-up of sirolimus-eluting stents for left main coronary artery revascularization. J. Am. Coll. Cardiol. (2006) 47:871-877.
37. ARAMPATZIS CA, LEMOS PA, TANABE K et al.: Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am. J. Cardiol. (2003) 92:327-329.
38. ARAMPATZIS CA, HOYE A, SAIA F et al.: Elective sirolimus-eluting stent implantation for left main coronary artery disease: six month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc. Interv. (2004) 62:292-296.
39. KERNER A, GRUBERG L, KAPERLIOVICH M, GRENADIER E: Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc. Interv. (2003) 60:505-508.
40. RIGATTIERI S, PATRIZI R, SILVESTER P et al: Very late thrombosis of a drug-eluting scent deployed during primary angioplasty for ST elevated myocardial infarction. J. Cardiovasc. Med. (Hagerstown) (2006) 7:775-778.
41. LEE CH, Lim J, LOW A, TAN HC, LIM YT: Late angiographic stent thrombosis of polymer based paclitaxel eluting stent. Heart (2006) 92:551-553.
42. JONER M, FINN AV, FARB A et al: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. (2006) 48:193-202.
43. CHEN JL, GAO RL, YANG YJ et al.: Comparison of short- and mid-term outcomes between CYPHER and TAXUS stents in patients with complex lesions of the coronary arteries. Chin. Med. J. (Engl.) (2006) 119:21-25.
44. SIANOS G, VAINA S, HOYE A, SERRUYS PW: Bifurcation stenting with drug eluting stents: illustration of the crush technique. Catheter Cardiovasc. Interv. (2006) 67:839-845.
45. MOUSSA I, COSTA RA, LEON MB et al: A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the 'crush technique'. Am. J. Cardiol. (2006) 97:1317-1321.
46. DOUGLAS JS, HOLMES DR, KAREIAKES DJ et al: Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 112:2826-2832.
47. MARXN, WOHRLE J, NUSSER T et al.: Pioglitazone reduces neointima volume after coronary stent implantation: are randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation (2005) 112:2792-2798.
48. SHOMIG A, KASTRATI A, WESSLEY R: Prevention of restenosis by systemic drug therapy back to future? Circulation (2005) 112:2759-2761.